End-of-day quote
Nasdaq
23:00:00 14/05/2024 BST
|
5-day change
|
1st Jan Change
|
13.35
USD
|
0.00%
|
|
+0.45%
|
+16.29%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
308.8
|
2,486
|
3,048
|
3,774
|
-
|
-
|
Enterprise Value (EV)
1 |
308.8
|
3,165
|
3,959
|
5,182
|
5,049
|
4,516
|
P/E ratio
|
-0.8
x
|
-3.85
x
|
-4.72
x
|
-22.6
x
|
130
x
|
19.8
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
1.37%
|
Capitalization / Revenue
|
8.4
x
|
29.9
x
|
32.6
x
|
10.7
x
|
6.22
x
|
4.34
x
|
EV / Revenue
|
8.4
x
|
38.1
x
|
42.4
x
|
14.7
x
|
8.33
x
|
5.19
x
|
EV / EBITDA
|
-
|
-9.71
x
|
-12
x
|
85.4
x
|
16.3
x
|
9.2
x
|
EV / FCF
|
-
|
-9.04
x
|
-11.5
x
|
106
x
|
24.9
x
|
12.1
x
|
FCF Yield
|
-
|
-11.1%
|
-8.72%
|
0.95%
|
4.02%
|
8.24%
|
Price to Book
|
-
|
-4.41
x
|
-2.8
x
|
-2.82
x
|
-4
x
|
-8.94
x
|
Nbr of stocks (in thousands)
|
31,250
|
248,650
|
265,530
|
279,567
|
-
|
-
|
Reference price
2 |
9.880
|
10.00
|
11.48
|
13.50
|
13.50
|
13.50
|
Announcement Date
|
10/05/22
|
01/03/23
|
20/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
36.77
|
83.03
|
93.38
|
352.7
|
606.4
|
870.5
|
EBITDA
1 |
-
|
-326
|
-330.6
|
60.7
|
309.6
|
490.9
|
EBIT
1 |
-
|
-346.4
|
-354.9
|
20.11
|
233.7
|
410.7
|
Operating Margin
|
-
|
-417.25%
|
-380.01%
|
5.7%
|
38.53%
|
47.18%
|
Earnings before Tax (EBT)
1 |
-
|
-551.6
|
-651
|
-184.2
|
33.57
|
224.3
|
Net income
1 |
-
|
-513.6
|
-551.7
|
-149.2
|
30.35
|
179.5
|
Net margin
|
-
|
-618.55%
|
-590.83%
|
-42.3%
|
5.01%
|
20.63%
|
EPS
2 |
-12.29
|
-2.600
|
-2.430
|
-0.5962
|
0.1037
|
0.6816
|
Free Cash Flow
1 |
-
|
-350.3
|
-345.4
|
49
|
203
|
372
|
FCF margin
|
-
|
-421.86%
|
-369.9%
|
13.89%
|
33.48%
|
42.73%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
80.73%
|
65.57%
|
75.78%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
668.79%
|
207.2%
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
0.1850
|
Announcement Date
|
10/05/22
|
01/03/23
|
20/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2023 Q2
|
---|
Net sales
|
-
|
EBITDA
|
-
|
EBIT
|
-
|
Operating Margin
|
-
|
Earnings before Tax (EBT)
|
-
|
Net income
1 |
189.3
|
Net margin
|
-
|
EPS
2 |
0.8500
|
Dividend per Share
|
-
|
Announcement Date
|
30/08/23
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
678
|
911
|
1,407
|
1,275
|
742
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-2.08
x
|
-2.755
x
|
23.19
x
|
4.119
x
|
1.512
x
|
Free Cash Flow
1 |
-
|
-350
|
-345
|
49
|
203
|
372
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-72%
|
-62%
|
-12.2%
|
4.93%
|
13.4%
|
Assets
1 |
-
|
713.2
|
889.3
|
1,225
|
616.3
|
1,343
|
Book Value Per Share
2 |
-
|
-2.270
|
-4.100
|
-4.780
|
-3.370
|
-1.510
|
Cash Flow per Share
2 |
-
|
-1.580
|
-1.370
|
0.2400
|
1.160
|
1.800
|
Capex
1 |
-
|
37.9
|
33.2
|
32.1
|
7.76
|
7.76
|
Capex / Sales
|
-
|
45.62%
|
35.59%
|
9.11%
|
1.28%
|
0.89%
|
Announcement Date
|
10/05/22
|
01/03/23
|
20/03/24
|
-
|
-
|
-
|
Last Close Price
13.5
USD Average target price
16.5
USD Spread / Average Target +22.22% Consensus |
1st Jan change
|
Capi.
|
---|
| +16.29% | 3.77B | | +41.79% | 50.93B | | -0.56% | 42.12B | | +49.62% | 42.05B | | -7.20% | 29.18B | | +12.59% | 26.02B | | -21.51% | 18.9B | | +6.92% | 13.21B | | +24.91% | 12.17B | | +29.60% | 12.16B |
Other Biotechnology & Medical Research
|